Genexine, Inc.

KOSDAQ 095700.KQ

Genexine, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 47.35

Genexine, Inc. Price to Sales Ratio (P/S) is 47.35 on January 14, 2025, a -50.57% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Genexine, Inc. 52-week high Price to Sales Ratio (P/S) is 95.80 on January 15, 2024, which is 102.32% above the current Price to Sales Ratio (P/S).
Genexine, Inc. 52-week low Price to Sales Ratio (P/S) is 46.00 on December 09, 2024, which is -2.86% below the current Price to Sales Ratio (P/S).
Genexine, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 69.92.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 095700.KQ

Genexine, Inc.

CEO	Dr. Jungwon Woo Ph.D.
IPO Date	Sept. 15, 2009
Location	South Korea
Headquarters	Korea Bio Park Building B
Employees	86
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.

Key trends

Past 5 years